MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Inclusion Criteria: * Ability and willingness of participant to provide written informed consent. * HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load. * On a potent, stable, continuous ART regimen for ≥ 24 months prior to Screening. * Plasma HIV-1 RNA \< 50 copies/mL at two time points in the previous 12 months prior to screening (one time point can be screening) and never ≥ 50 copies/mL on 2 consecutive time points in the last 24 months. * Adequate organ function based on acceptable laboratory parameters. Exclusion Criteria: * Women of childbearing potential defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or menopause. * History or other evidence of severe illness, immunodeficiency other than HIV, or any other condition that would make the potential participant unsuitable for study. * History or other evidence of any condition or process for which signs or symptoms could be confused with reactions to MGD014. * History of any HIV immunotherapy or HIV vaccine except for MGD014 within 12 months prior to screening. * History of clinically significant cardiovascular disease, severe allergic reactions, malignancy (except non-melanoma skin cancer) within 5 years, seizure disorder within 2 years, organ/tissue transplant, autoimmune disease, unstable asthma, bleeding disorder. * Evidence of active viral, or antifungal treatment within 7 days prior to the initiation of study drug * Active, asymptomatic, or suspected COVID-19/SARS-CoV-2 infection. * Active, untreated syphilis. * Use of blood products, cytokine therapy, growth-stimulating factors, cytotoxic chemotherapy or investigational therapy within 90 days. * Current use of the antivirals maraviroc and/or enfuvirtide. * Any vaccination with exception of flu vaccine within 30 days of screening.